Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Semafor and Gizmodo. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 111d ago.
Quick answers
Why is "Kalshi comes for biopharma, with prediction markets for clinical trials and FDA " trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Kalshi bets on Wall Street Semafor · 124d ago
- Kalshi Is Set to Start Taking Bets on Drug Trials Gizmodo · 124d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Exclusive: Nine Democratic Senators Ask CFTC Not to Interfere With State Bans on Prediction Markets
Nine Democratic senators urge the CFTC to respect state bans on prediction markets, escalating a federal-state clash over platforms like Kalshi and Polymarket.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Traders Turn to Kalshi Stock ‘Perps’ on Nvidia and SpaceX as Leverage Fears Grow
Traders are flocking to Kalshi's stock perpetuals on Nvidia and SpaceX as leverage fears grow.